Efficacy of Pentoxifylline on Chronic Kidney Disease
Chronic Kidney Disease
About this trial
This is an interventional treatment trial for Chronic Kidney Disease focused on measuring CKD, pentoxifylline
Eligibility Criteria
Inclusion Criteria: Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl Exclusion Criteria: History of allergy to pentoxifylline Females are nursing or pregnant Obstructive uropathy Unable to stop chronic immunosuppressive therapy, NSAID Congestive heart failure (New York Heart Association functional class III or IV) Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form Cerebral hemorrhage within the past 6 months prior to signing the informed consent form Retinal hemorrhage within the past 6 months prior to signing the informed consent form Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma) Severe uncontrolled hypertension with SBP > 220 mmHg and/or DBP > 115 mmHg Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 2 times the upper limit of the normal range Biliary obstructive disorders (e.g. cholestasis) Active malignancy
Sites / Locations
- National Taiwan University Hospital